Trials / Completed
CompletedNCT05715320
Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double Blind, Parallel-controlled Phase 2 Study to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Subjects With Moderate-to-severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, randomized, double-blind, parallel controlled phase 2 study, aimed at evaluating the efficacy and safety of CM310 in the treatment of patients with moderate-to-severe atopic dermatitis, and observing Pharmacokinetics characteristics, Pharmacodynamics effects and immunogenicity.
Detailed description
This study includes screening, treatment and follow-up periods. 160 subjects will be enrolled to receive CM310.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM310 | IL-4Rα monoclonal antibody |
Timeline
- Start date
- 2023-03-10
- Primary completion
- 2024-07-18
- Completion
- 2024-07-18
- First posted
- 2023-02-08
- Last updated
- 2024-10-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05715320. Inclusion in this directory is not an endorsement.